Genentech - A Member of the Roche Group

/ Media

Statements

Read our formal press statements on significant topics and events.

17 Jan 2013

Update on Tamiflu Supply

Genentech has released a reserve stock of Tamiflu® (oseltamivir phosphate) 75 mg capsules that carry different packaging from what is currently available on the market in the U.S.

2 Jun 2010

Statement on MAIN trial

Genentech, Inc. announced today that it has accepted the recommendation of an independent Data and Safety Monitoring Board (DSMB) to stop enrollment into the MAIN trial, a Phase III clinical study evaluating the efficacy and safety of Avastin® (bevacizumab) when added to Rituxan® (rituximab) plus CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy in patients with Diffuse Large B-Cell Lymphoma (DLBCL).

27 May 2010

Statement on supplemental Biologics License Applications for Avastin® (bevacizumab)

Genentech, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's two supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer during an advisory committee meeting on July 20, 2010.

9 Mar 2009

Statement on FDA discussion of supplemental Biologics License Application

Genentech, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) for people with previously treated glioblastoma during an advisory committee meeting on March 31, 2009.